A STUDY TO COMPARE THE EFFECTIVENESS. METFORMIN AND METFORMIN + GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES

Dr. Vishnu A. Kangralkar* and Dr. Anilkumar S. Kusnoor

Background: Type 2 diabetes mellitus (T2DM) requires effective glycemic control to prevent complications. Metformin is the first-line therapy, but many patients need combination treatment for optimal control. This study compared the efficacy and safety of Metformin monotherapy versus Metformin + Glimepiride combination therapy. Methods: A total of 100 T2DM patients were randomized into two groups (n=50 each). Group A received Metformin, while Group B received Metformin + Glimepiride for 12 weeks. Glycemic parameters (HbA1c, FBG, PPBG), BMI, medication adherence, and adverse events were assessed at baseline and 12 weeks. Results: Both groups showed significant reductions in HbA1c, FBG, and PPBG. Group B demonstrated greater reductions (HbA1c: 1.5% vs 1.0%; FBG: 29 vs 20 mg/dL; PPBG: 47 vs 30 mg/dL; p<0.05). BMI remained stable. Adherence was high, and side effects were mild. Conclusion: Metformin + Glimepiride combination therapy provides superior glycemic control compared to Metformin alone, with good safety and adherence, making it an effective treatment option for T2DM patients not achieving targets with monotherapy.